EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of baseline 18F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving 177Lu-PSMA-targeted radioligand therapy

Amir Karimzadeh, Kimberley Hansen, Stefan Hein, Bernhard Haller, Matthias M Heck, Robert Tauber, Calogero D Alessandria, Matthias Eiber, Isabel Rauscher

European Journal of Nuclear Medicine and Molecular Imaging · 2025-10 · 52 (12) · 4434-4445

DOI: 10.1007/s00259-025-07200-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 19.05.2025. Verfasst von Amir Karimzadeh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, School of Medicine and Health, TUM University Hospital, Munich, Germany. amir.karimzadeh@uke.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Bone Neoplasms, Hematologic Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum rechts der Isar der Technischen Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This retrospective analysis evaluated the prognostic value of baseline 18 F-flotufolastat-PET bone tumor metrics for severe hematologic toxicity in metastatic castration-resistant prostate cancer (mCRPC) patients treated with [ 177 Lu]Lu-PSMA-I&T.

Methods

Data from 182 mCRPC patients with baseline 18 F-flotufolastat-PET scans and complete hematologic profiles were analyzed. Bone lesions were semiautomatically delineated, and clinical parameters (e.g., pretreatments, lab results) were assessed. Hematologic adverse events (AEs) were defined per Common Terminology Criteria for Adverse Events version 5.0, with grades 3–4 considered severe. Cox regression was used to identify prognostic factors for AEs.

Results

Baseline bone tumor volume prognosticated leukocytopenia (HR 1.03 per 100 ml, p = 0.036), while the number of bone lesions was prognostic for anemia (HR 1.04 per 10 lesions, p < 0.001) and severe anemia (HR per 10 lesions 1.05, p = 0.009). Higher baseline hemoglobin correlated with reduced leukocytopenia (HR 0.74, p = 0.002), thrombocytopenia (HR 0.80, p = 0.033), and severe anemia (HR 0.52, p < 0.001). Baseline kidney dysfunction was linked to anemia (HR 2.46, p = 0.002) and severe anemia (HR 3.81, p = 0.023). Prior [ 223 Ra]Radiumdichloride treatment prognosticated severe thrombocytopenia (HR 6.43, p = 0.021).

Conclusion

Baseline 18 F-flotufolastat-PET metrics and pretherapeutic clinical parameters are key prognostic factors for severe hematologic toxicity in mCRPC patients treated with [ 177 Lu]Lu-PSMA-I&T.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantBone NeoplasmsHematologic DiseasesHumansMaleAgedLutetiumMiddle AgedPrognosisRetrospective StudiesTumor BurdenAged, 80 and overRadiopharmaceuticalsRadioisotopesGlutamate Carboxypeptidase IIProstate-Specific Antigen

Stichwörter der Autor:innen

Bone tumor metricsHematologic toxicityPSMA radioligand therapy[177Lu]Lu-PSMA-I&T; mCRPC

Substanzen

LutetiumLutetium-177RadiopharmaceuticalsPluvictoRadioisotopesGlutamate Carboxypeptidase IIProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Nuclear Medicine, School of Medicine and Health, TUM University Hospital, Munich, Germany. amir.karimzadeh@uke.de.
  • Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany. amir.karimzadeh@uke.de.
  • Department of Nuclear Medicine, School of Medicine and Health, TUM University Hospital, Munich, Germany.
  • School of Medicine and Health, Institute of AI and Informatics in Medicine, Technical University of Munich, TUM University Hospital, Munich, Germany.
  • Department of Urology, School of Medicine and Health, TUM University Hospital, Munich, Germany.
  • Bavarian Cancer Research Center, Munich, Germany.

Förderung

  • Klinikum rechts der Isar der Technischen Universität München

Zitieren

APA

Karimzadeh, A., Hansen, K., Hein, S., Haller, B., Heck, M. M., Tauber, R., D Alessandria, C., Eiber, M., & Rauscher, I. (2025). Impact of baseline 18F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving 177Lu-PSMA-targeted radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging, 52(12), 4434-4445. https://doi.org/10.1007/s00259-025-07200-7

Vancouver

Karimzadeh A, Hansen K, Hein S, Haller B, Heck MM, Tauber R, et al. Impact of baseline 18F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving 177Lu-PSMA-targeted radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(12):4434-4445. doi:10.1007/s00259-025-07200-7

BibTeX
@article{Karimzadeh2025,
  author = {Karimzadeh, Amir and Hansen, Kimberley and Hein, Stefan and Haller, Bernhard and Heck, Matthias M and Tauber, Robert and D Alessandria, Calogero and Eiber, Matthias and Rauscher, Isabel},
  title = {Impact of baseline 18F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving 177Lu-PSMA-targeted radioligand therapy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {12},
  pages = {4434--4445},
  doi = {10.1007/s00259-025-07200-7}
}
Kostenlos starten →